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OBJECTIVES We tested the hypothesis that thinner-strut stents are associated with a reduced rate of
restenosis when comparing two stents with different design.
BACKGROUND We have previously shown that, for two stents with similar design, the risk for restenosis is
dependent on the strut thickness. It is unknown whether strut thickness preserves its relevance
as a determinant of restenosis even in the presence of different stent designs.
METHODS A total of 611 patients with symptomatic coronary artery disease were randomly assigned to
receive either the thin-strut ACS RX Multilink stent (Guidant, Advanced Cardiovascular
Systems, Santa Clara, California) (strut thickness 50 m, interconnected ring design; n 
309) or the thick-strut BX Velocity stent (Cordis Corp., Miami, Florida) (strut thickness 140
m, closed cell design; n  302). The primary end point was angiographic restenosis (50%
diameter stenosis at follow-up angiography). Secondary end points were the incidence of
target-vessel revascularization (TVR) and the combined rate of death and myocardial
infarction (MI) at one year.
RESULTS The incidence of angiographic restenosis was 17.9% in the thin-strut group and 31.4% in the
thick-strut group, relative risk, 0.57 (95% confidence interval, 0.39 to 0.84), p  0.001. A
TVR due to restenosis was required in 12.3% of the thin-strut group and 21.9% of the
thick-strut group, relative risk, 0.56 (95% confidence interval, 0.38 to 0.84), p  0.002. No
significant difference was observed in the combined incidence of death and MI at one year.
CONCLUSIONS When two stents with different design are compared, the stent with thinner struts elicits less
angiographic and clinical restenosis than the thicker-strut stent. (J Am Coll Cardiol 2003;
41:1283–8) © 2003 by the American College of Cardiology Foundation
Stenting has become the dominant percutaneous coronary
intervention (1). An increasing number of randomized
clinical trials have demonstrated that stent characteristics
are an important determinant of restenosis (2–7). Although
the exact underlying mechanisms of this influence are not
clearly understood, stent architecture (2,3,8), material com-
position of stent surface (4–6), and strut thickness (7,9)
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have been indicated as factors that may affect the process of
restenosis after stent implantation. In the Intracoronary
Stenting and Angiographic Results: Strut Thickness Effect
on Restenosis Outcome (ISAR-STEREO) trial (7), pa-
tients were randomly assigned to receive one of two stents
with similar interconnected ring design but a different strut
thickness. One year after stenting, patients who received
stents with thin struts had a considerably lower restenosis
rate than those receiving thick-strut stents (7). The magni-
tude of difference in restenosis in the ISAR-STEREO (42%
risk reduction with the thin-strut stent) suggests that strut
thickness plays a major role in this process, with relevant
implications for stent technology (7). However, the ISAR-
STEREO trial could not answer the question of whether
the role of strut thickness is evident only when comparing
two stents with similar interconnected ring design and is not
applicable for stents with different design. This was the
rationale of the present trial, ISAR-STEREO-2, in which
the objective was to assess the influence of strut thickness on
restenosis when two stents with different design are com-
pared.
METHODS
This randomized, multicenter study included 611 patients
with symptomatic coronary artery disease and coronary
From the *Deutsches Herzzentrum, Munich, Germany; †1. Medizinische Klinik
rechts der Isar, Munich, Germany; ‡Medizinische Klinik I, Garmisch-Partenkirchen,
Germany; and §Medizinische Klinik I, Ingolstadt, Germany. Supported, in part, by
unrestricted educational grants from the Technische Universita¨t, Munich, Germany,
and Cordis Medizinische Apparate GmbH, Haan, Germany. Presented as a Late-
Breaking Clinical Trial during the 51st Annual Scientific Session of the American
College of Cardiology, March 17–20, 2002, Atlanta, Georgia. Please see the
Appendix for the complete list of the centers and investigators participating in the
ISAR-STEREO 2 trial.
Manuscript received April 23, 2002; revised manuscript received June 17, 2002,
accepted June 26, 2002.
Journal of the American College of Cardiology Vol. 41, No. 8, 2003
© 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00
Published by Elsevier Science Inc. doi:10.1016/S0735-1097(03)00119-0
lesions situated in native vessels and was conducted accord-
ing to the principles of the Declaration of Helsinki and
approved by the local ethics committees. All patients had
given their informed consent for participation in this trial.
After successful passage of the guidewire through the
target vessel, the patients were randomly assigned to receive
one of the following two premounted stent types: the
thin-strut stent, ACS RX Multi-Link (Guidant, Advanced
Cardiovascular Systems, Santa Clara, California), has a strut
thickness of 50 m, a strut width of 100 m, and an
interconnected ring design; it was available in lengths of 15,
25, and 35 mm. The thin-strut stent model is no longer
commercially available. The thick-strut stent, BX Velocity
(Cordis Corporation, Miami, Florida), has a strut thickness
of 140 m, a strut width of 130 m, and a closed cell
design; it was available in lengths of 8, 13, 18, 23, 28, and
33 mm. The operator decided which balloon pressure to use
for final stent expansion on the basis of the evidence
provided by previous randomized trials (10). The procedure
was considered successful when stent placement was asso-
ciated with a residual stenosis of 30% and Thrombolysis
in Myocardial Infarction flow grade 2. During the inter-
vention, patients received heparin and aspirin, intrave-
nously. The patients considered at a higher risk for throm-
botic events (e.g., patients with acute myocardial infarction
(MI), thrombus-containing lesions, and suboptimal proce-
dural results) received abciximab as a bolus, followed by a
12-h intravenous infusion and heparin dosage reduced by
50%. Post-procedural therapy comprised aspirin 100 mg
twice daily indefinitely and clopidogrel 75 mg/day for at
least four weeks. A follow-up angiography at six months
was scheduled for all patients.
Quantitative coronary angiographic evaluation. Opera-
tors of the core angiographic laboratory who performed the
quantitative assessment were blinded to the randomly as-
signed treatment. Angiograms recorded before and imme-
diately after the procedure as well as at six-month follow-up
were assessed with the aid of the automated edge-detection
system CMS (Medis Medical Imaging System, Nuenen, the
Netherlands). All measurements were performed on cinean-
giograms recorded after intracoronary nitroglycerin admin-
istration. The same projections were used at all time points.
The contrast-filled non-tapered catheter tip was used for
calibration. Early lumen gain was calculated as the differ-
ence between minimal lumen diameter at the end of the
intervention and before the balloon dilation. Late lumen
loss was the difference in the minimal lumen diameter
between that immediately after the procedure and that at
follow-up, and loss index was the ratio between late lumen
loss and early lumen gain. Angiographic restenosis was
defined as a diameter stenosis 50% at follow-up angiog-
raphy measured at any point within the stented segment or
in the 5-mm proximal or distal segments adjacent to the
stent.
Clinical evaluation. Adverse events were monitored
throughout the follow-up period: by telephone interview at
30 days, a clinical visit at six months, and an additional
telephone interview at one year after the intervention. If
patients reported cardiac symptoms during the telephone
interview, at least a clinical and electrocardiographic
follow-up visit was performed at the outpatient clinic or by
the referring physician. All information available from
hospital re-admission records, the referring physician, or the
outpatient clinic was entered into a computer database.
Death, MI, and target-vessel revascularization (TVR) (per-
cutaneous transluminal coronary angioplasty or bypass sur-
gery) were considered as adverse events. The diagnosis of
acute MI required the presence of at least two of the
following criteria: prolonged (20-min duration) and typ-
ical chest pain, new pathological Q waves on the electro-
cardiogram, and an increase of creatine kinase (CK) or its
MB isoenzyme 2 times the upper limit; CK was deter-
mined before and immediately after the procedure, every 8 h
for the first 24 h after stenting, and daily afterward until
discharge. The criteria for TVR included the presence of
restenosis accompanied by symptoms and/or positive exer-
cise test.
End points of the study and sample size calculation. The
primary end point of the study was the incidence of
angiographic restenosis (see the definition in the preceding
text). The sample size of the trial was calculated on the basis
of the findings of a previous randomized trial (7): a 15.0%
restenosis rate with the thin-strut stent and 25.8% with the
thick-strut stent. We intended to be able to show a similar
difference for the two stents in this study as well, with an
80% power and a two-sided -level of 0.05. To achieve this
objective, 440 patients with follow-up angiography were
required. We included 611 patients to accommodate for
expected missing angiographic examinations at six months.
Secondary end points focused on clinical events occurring
during one year after the procedure: the incidence of TVR
and the combined incidence of death and MI.
Statistical analysis. The main analyses were performed on
an intention-to-treat basis. Data are presented as mean 
SD or as proportions (%). The differences between groups
were assessed by chi-square test or Fisher exact test for
categorical data and t test for continuous data. Survival
Abbreviations and Acronyms
CK  creatine kinase
ISAR-STEREO  Intracoronary Stenting and
Angiographic Results: Strut
Thickness Effect on Restenosis
Outcome trial
MI  myocardial infarction
RAVEL  Randomized Study With the
Sirolimus Coated Velocity Balloon
Expandable Stent in the Treatment
of Patients With De Novo Native
Coronary Lesions trial
RR  relative risk
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parameters were compared using the log-rank test. The
relative risk (RR) and its 95% confidence interval (CI) were
calculated for each study end point. A p value  0.05 was
considered statistically significant.
RESULTS
Table 1 shows the baseline clinical characteristics of the
patients in the two groups defined by the randomly assigned
device, and no statistical difference is evident. Table 2
displays the baseline angiographic and hemodynamic char-
acteristics. Although the vast majority of the parameters
show no statistical difference, the lesions in the thin-strut
stent group were significantly more complex (p  0.001).
The group of the thick-strut stent showed, in turn, a trend
toward a higher proportion of patients with chronic occlu-
sions (p  0.06).
Procedural data. Table 3 shows the procedural data. A
significantly higher number of stents was implanted in the
patients of the thin-strut stent group (p  0.02). We
performed post-stent dilations with semi-compliant bal-
loons in the large majority of the patients. Actual maximal
balloon diameter measured in the quantitative coronary
angiographic core laboratory was not significantly different
between the two groups (Table 3) (p 0.62). Of note, there
were no differences in early lumen gain and final diameter
stenosis between the two groups. There was a high proce-
dural success rate in both groups according to the intention-
to-treat principle. However, although this success was
always achieved with the randomly assigned device in the
thick-strut stent group, the placement of a stent other than
that randomly assigned, was necessary in 38 patients of the
thin-strut group, which translated into a significantly lower
device success rate in the latter group (p 0.001). Of the 38
patients who received a stent other than the thin-strut
Table 1. Baseline Clinical Characteristics
Thin-Strut
(n  309)
Thick-Strut
(n  302)
p
Value
Age, yrs 66  11 66  12 0.94
Women, n (%) 79 (26) 75 (25) 0.84
Diabetes, n (%) 68 (22) 67 (22) 0.96
Current smoker, n (%) 66 (21) 65 (22) 0.96
Cholesterol level, mg/dl 209  54 211  47 0.53
Acute myocardial infarction,
n (%)
39 (13) 36 (12) 0.79
Unstable angina, n (%) 98 (32) 93 (31) 0.81
Previous myocardial infarction,
n (%)
54 (18) 69 (23) 0.10
Previous bypass surgery, n (%) 22 (7) 24 (8) 0.70
Data are mean  SD or number of patients (%).
Table 2. Baseline Angiographic and Hemodynamic Characteristics
Thin-Strut (n  309) Thick-Strut (n  302) p Value
Heart rate, min1 72.9  12.0 71.7  11.9 0.21
Mean arterial blood pressure, mm Hg 102.5  20.7 103.9  19.4 0.39
Left ventricular ejection fraction, % 57.7  15.5 58.1  15.0 0.73
Number of diseased vessels 0.41
One vessel, n (%) 96 (31) 80 (27)
Two vessels, n (%) 92 (30) 101 (33)
Three vessels, n (%) 121 (39) 121 (40)
Target vessel 0.79
Left main, n (%) 3 (1) 3 (1)
LAD, n (%) 138 (45) 123 (41)
LCx, n (%) 76 (24) 77 (25)
RCA, n (%) 92 (30) 99 (33)
Complex lesions (B2/C lesions)* 255 (82) 213 (70)  0.001
Chronic occlusions, n (%) 15 (5) 26 (9) 0.06
Restenotic lesions, n (%) 10 (3) 13 (4) 0.49
Lesion length, mm 13.9  7.8 14.1  7.8 0.77
Vessel size, mm 2.93  0.50 2.91  0.51 0.68
Diameter stenosis, % 68.2  18.9 70.8  20.4 0.11
*Lesion complexity was assessed on the basis of the modified classification of the American College of Cardiology/American
Heart Association. Data are mean  SD or number of patients (%).
LAD  left anterior descending coronary artery; LCx  left circumflex coronary artery; RCA  right coronary artery.
Table 3. Procedural Data
Thin-Strut
(n  309)
Thick-Strut
(n  302)
p
Value
Administration of abciximab,
n (%)
154 (50) 149 (49) 0.90
Multilesion intervention,
n (%)
122 (39) 114 (38) 0.66
Maximal balloon pressure,
atm
12.1  2.0 12.3  2.1 0.18
Maximal balloon diameter,
mm
3.39  0.51 3.37  0.51 0.62
Balloon-to-vessel ratio 1.17  0.15 1.17  0.15 0.90
Number of implanted stents 1.3  0.6 1.2  0.4 0.02
Length of stented segment,
mm
22.0  10.3 20.7  9.6 0.12
Early lumen gain, mm 1.97  0.61 2.00  0.66 0.54
Final minimal lumen
diameter, mm
2.89  0.48 2.85  0.52 0.32
Final diameter stenosis, % 4.3  9.7 4.2  11.6 0.78
Procedural success, n (%) 307 (99) 299 (99) 0.64
Device success, n (%) 269 (87) 299 (99)  0.001
Data are mean  SD or number of patients (%).
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model, 31 received the BX Velocity stent, four the AVE
stent (Medtronic, Minneapolis, Minnesota), and three the
Multi-Link Tetra stent (Guidant, Advanced Cardiovascular
Systems). Postprocedurally, an increase in CK or CK-MB
3 above the normal limit, as defined previously (11), was
observed in 17 patients (6.4%) of the thin-strut stent group
and 12 patients (4.5%) of the thick-strut stent group (p 
0.34).
Angiographic data at six months. Procedural failure,
death, or TVR during the first 30 days were considered
ineligibility criteria for the six-month angiography. Accord-
ingly, 10 patients (3.2%) of the thin-strut stent group and
six patients (2.0%) of the thick-strut stent group were
ineligible for follow-up angiography (p  0.33). Follow-up
angiography was carried out in 229 of the 299 eligible
patients (77%) of the thin-strut group and 236 of the 296
eligible patients (80%) of the thick-strut group (p  0.35).
Angiographic findings at follow-up are displayed in Table 4.
All parameters are concordant in showing a significantly
greater risk for lumen re-narrowing with the thick-strut
stent. Figure 1 shows that, although early lumen gain was
practically similar in both groups, late lumen loss was
significantly more considerable in the thick-strut stent
group.
The primary end point of the study, the incidence of
angiographic restenosis, was encountered in 17.9% of the
patients in the thin-strut group and 31.4% of the patients in
the thick-strut group (Fig. 2, left panel) (p  0.001). Thus,
the use of the thin-strut stent was associated with a 43%
reduction of the risk for restenosis, compared with the
thick-strut stent, RR, 0.57 (95% CI, 0.39 to 0.84).
We performed two additional analyses after excluding
specific subgroups of patients. When we excluded patients
who did not receive the randomly assigned stent, the
restenosis rates were 17.6% in the thin-strut group and
31.4% in the thick-strut group; when we excluded patients
with chronic occlusions, the restenosis rates were 16.6% in
the thin-strut group and 29.3% in the thick-strut group.
Clinical data at one-year follow-up. During one year after
the procedure, a TVR due to restenosis was required in 38
patients of the thin-strut group (12.3%) and 66 patients of
the thick-strut group (21.9%) (Fig. 2, right panel) (p 
0.002). This indicates a 44% risk reduction with the use of
the thin-strut stent (RR, 0.56 [95% CI, 0.38 to 0.84]).
During the same follow-up period, 15 patients of the
thin-strut group (4.9%) and 19 patients of the thick-strut
group (6.3%) died or incurred an MI (RR, 0.77 [95 CI, 0.39
to 1.52], p 0.46). No significant differences were observed
in one-year mortality rates, with 3.9% in the thin-strut
group and 4.6% in the thick-strut group (p  0.66).
DISCUSSION
We used two stainless steel stents with different architecture
and strut thickness. The thin-strut stent has been the first
model of interconnected ring design in the Multi-Link
series. Although several other stent models share a similar
design, the most peculiar characteristic of the thin-strut
stent used in the present study is its strut thickness of only
50 m. The thick-strut stent, BX-Velocity, has a strut
thickness of 140 m, similar to several other stents that are
currently used by interventional cardiologists. Its thickness
is identical to that of the thick-strut stent used in the
ISAR-STEREO trial (7). The thick-strut stent used in the
present trial has a closed-cell design markedly different from
that of the thick-strut stent implanted in the ISAR-
STEREO trial (7). The design of the BX-Velocity stent
enabled a high device success rate that was much better than
that achieved with the system carrying the ACS RX
Multi-Link thin-strut stent. The patients were followed up
for one year, and an angiography scheduled at six months
was performed in a high proportion of patients even in the
absence of symptoms. The stents assessed in our trial were
associated with a comparable one-year incidence of death
and MI. The main finding of the study indicates, however,
that when two stents with different design are compared,
the stent with thinner struts elicits less angiographic and
clinical restenosis.
Comparison with previous trials. The incidence of reste-
nosis at follow-up angiography with the thin-strut stent was
17.9%. This appears to be slightly higher than the incidence
Figure 1. Cumulative distribution curves of early (“acute”) lumen gain
(enlargement of lumen achieved by stenting and measured immediately
after the procedure) and late lumen loss (lumen narrowing occurred during
the period between intervention and follow-up angiography at 6 months).
Note that similar early results (as indicated by the curves depicting early
lumen gain) do not necessarily translate into similar results at 6 months (as
indicated by the curves depicting late lumen loss).
Table 4. Angiographic Data at Follow-up
Thin-Strut
(n  229)
Thick-Strut
(n  236)
p
Value
Minimal lumen diameter, mm 1.96  0.76 1.70  0.83  0.001
Diameter stenosis, % 33.4  21.5 42.4  24.1  0.001
Late lumen loss, mm 0.93  0.61 1.19  0.69  0.001
Loss index 0.51  0.37 0.65  0.44  0.001
Incidence of restenosis, n (%) 41 (17.9) 74 (31.4)  0.001
Data are mean  SD or number of patients (%).
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of restenosis of 15.0% reported from in the previous
ISAR-STEREO trial with the same stent type (7). The
reason may be found in the difference in vessel size between
the populations included in the two ISAR-STEREO trials,
with smaller coronary vessels treated in the present trial.
Altogether, the findings of the ISAR-STEREO trials as
well as those of another randomized trial (12) demonstrate
that consistently low restenosis rates can be achieved with
thin-strut stents.
In the present trial, the incidence of restenosis at
follow-up angiography with the thick-strut stent was 31.4%.
The same type of stent has been used in the uncoated stent
arm of the Randomized Study With the Sirolimus Coated
Velocity Balloon Expandable Stent in the Treatment of
Patients With de novo Native Coronary Lesions (RAVEL)
(13). In the RAVEL trial, which included a control group of
118 patients treated with the uncoated BX-Velocity stent,
the angiographic restenosis rate in this arm was 26% (13).
Considering that the study lesions in the ISAR-STEREO
2 trial were more complex, there is essentially no difference
between our trial and the RAVEL trial with respect to the
incidence of angiographic restenosis observed in the un-
coated, thick-strut arm. Consistent with these results are
also the findings of clinical restenosis, with a revasculariza-
tion rate of 21.9% in the present trial and 22% in the
RAVEL trial (13).
Clinical implications. Although there was no difference in
mortality and the incidence of MI, the group assigned to the
thin-strut stent had a 43% decrease in the risk for restenosis
at follow-up angiography and a 44% reduction in the risk for
re-intervention, compared with the group assigned to the
thick-strut stent. Similar reduction in the risk for restenosis
was also observed in the group of the thin-strut stent in the
first ISAR-STEREO trial (7). The consistent reduction of
restenosis with the thin-strut stent compared with two
thick-strut stents with different architecture in both ISAR-
STEREO trials strongly supports a role for the strut
thickness that is largely independent of other stent charac-
teristics. We do not know the exact mechanisms underlying
the reduction of restenosis after the use of thin-strut stents.
A few possibilities have already been discussed in the
previous publication on the same subject (7). Despite the
paucity of the mechanistic data that may help to explain the
influence of strut thickness on restenosis (9), the findings of
the present trial have important implications because most
of the stents currently in use have a strut thickness similar to
that of the thick-strut stent used in this and in the previous
ISAR-STEREO trial. Drug-eluting stent technology has
surely opened new promising prospects for our efforts
against restenosis (13), and hopefully, large studies in the
near future will be able to prove the abolishment of
restenosis through this technology.
Study limitations. The design of the present study aimed
at complementing the previous ISAR-STEREO trial (7).
Although both trials suggest a relevant role for strut
thickness in in-stent restenosis, other stent-related factors
might also have contributed to the differences in restenosis
observed between the study groups. The impact of stent
geometry on restenosis has not been evaluated in controlled
clinical trials, and it is not known which geometrical
characteristics enable reduction of restenosis. The differ-
ences in stent geometry between the thick- and the thin-
strut models, which were subtle in the previous ISAR-
STEREO trial (7) and much more conspicuous in the
present trial, might also have contributed to the overall
better result achieved with the thin-strut stent. Therefore,
further work is needed to quantify the degree in which strut
thickness per se influences in-stent restenosis and to identify
the optimal strut thickness to use during stent manufactur-
ing.
Two additional limitations should also be acknowledged.
First, due to the failure of thin-strut device, the procedural
success in 12% of the patients in the thin-strut group was
achieved after crossover to the thick-strut model. We tried
to adjust for this inconvenience by performing an additional
analysis confined to patients without crossover, but both the
Figure 2. Incidence of angiographic (left) and clinical (right) restenosis in each group.
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nature and magnitude of the possible bias introduced by the
crossover phenomenon remain still unknown. Second, the
difference in radiolucency between the thin- and the thick-
strut models might have interfered with the quantitative
angiographic assessment. A specifically designed study con-
cluded that quantitative angiography can be used as an
accurate method of lumen assessment after implantation of
steel stents with different thickness and that only the highly
opaque tantalum stent may reduce the accuracy to some
degree (14). However, our angiographic data are also
supported by the incidence of reinterventions, which favors
the thin-strut model.
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APPENDIX
The following centers and investigators participated in the
ISAR-STEREO-2 trial:
Steering Committee: A. Scho¨mig (chairman), A. Kastrati,
J. Dirschinger.
Data Coordinating Center: A. Kastrati, M. Hadamitzky,
Deutsches Herzzentrum, Munich.
Angiographic Core Laboratory: J. Mehilli, A. Redl, D.
Kiemoser, S. Pinieck, Deutsches Herzzentrum, Munich.
Clinical Follow-up Center: H. Holle, K. Ho¨sl, F.
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